Related Experiment Video
Updated: Sep 16, 2025
05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
5.7K
Cerebral Venous Sinus Thrombosis During Raloxifene Therapy: A Case Report
Shunsuke Kimura1, Tadataka Mizoguchi1, Yusuke Imamura1
1Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center, Fukuoka, JPN.
Cureus
|July 8, 2025
Summary
Raloxifene, used for osteoporosis, may be linked to cerebral venous sinus thrombosis (CVST), a rare but serious condition causing brain hemorrhage and seizures. This case highlights a potential adverse effect of this medication.
Area of Science:
- Neurology
- Pharmacology
- Radiology
Background:
- Osteoporosis management often involves medications like raloxifene.
- Raloxifene is known to have thrombotic events as a potential adverse effect.
- Cerebral venous sinus thrombosis (CVST) is a rare cerebrovascular condition.
Observation:
- A 79-year-old woman on raloxifene presented with hemiplegia and seizures.
- Head CT revealed subcortical hemorrhage.
- CT venography identified superior sagittal sinus disruption, confirming CVST.
Findings:
- Raloxifene was identified as a potential contributing factor to CVST in the absence of other thrombogenic risks.
- The patient was treated with anticoagulation (heparin and warfarin) without clinical worsening.
- CVST is an uncommon but recognized adverse effect associated with raloxifene therapy.
Implications:
- This case underscores the importance of considering raloxifene as a potential cause of CVST.
- Clinicians should be vigilant for rare thrombotic events in patients taking raloxifene.
- Further research may be warranted to elucidate the precise mechanism linking raloxifene to CVST.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
45
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
45
01:30Venous Thrombosis IV: Nursing Management
25
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
25
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
41
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
41
01:29Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
702
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
702